3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
15
Gynecologic
9
Thoracic
8
Genitourinary
8
Head & Neck
5
Dermatologic
3
NET
2
Endocrine
2
CNS
2
Breast
2
Sarcoma
1
Conditions
Sarcoma
316
Gastrointestinal Stromal Tumors
108
Neoplasms
105
Breast Neoplasms
92
Melanoma
81
Ovarian Neoplasms
79
Neoplasm Metastasis
74
Carcinoma, Non-Small-Cell Lung
73
Colorectal Neoplasms
69
Osteosarcoma
61
Stomach Neoplasms
59
Pancreatic Neoplasms
55
Bone Neoplasms
55
Prostatic Neoplasms
51
Head and Neck Neoplasms
48
Glioblastoma
48
Sarcoma, Ewing
47
Lung Neoplasms
45
Esophageal Neoplasms
42
Squamous Cell Carcinoma of Head and Neck
41
Carcinoma, Renal Cell
40
Uterine Cervical Neoplasms
39
Sarcoma, Kaposi
38
Lymphoma
37
Urinary Bladder Neoplasms
36
Sarcoma, Synovial
36
Recurrence
35
Dendritic Cell Sarcoma, Interdigitating
34
Lymphoma, Non-Hodgkin
33
Endometrial Neoplasms
33
Interventions
interferon gamma-1b
1
Oncolytic Virotherapy
1
Interferon-gamma
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled